v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue $ 33 $ 6 $ 55 $ 14
Operating expenses:        
Cost of revenue 122 41 219 78
Sales and marketing 215 220 430 467
General and administrative 4,651 3,670 11,008 8,053
Research and development 2,067 790 3,455 1,576
Total operating expenses 7,055 4,721 15,112 10,174
Operating loss (7,022) (4,715) (15,057) (10,160)
Other income (expense):        
Interest income 10 8 29 14
Interest expense (2) (4) (5) (7)
Change in fair value - equity method investment (2,504) (10,643) (626) 10,361
Change in fair value - Senior Secured Convertible Notes (565) (200) 2,795 (249)
Debt extinguishments loss - Senior Secured Convertible Notes 0 0 (3,422) (58)
Change in fair value - warrant liability 0 0 1,831 0
Management fee income 3,150 3,150 6,300 6,300
Grant income 311 80 480 99
Other expense 0 0 (41) 0
Other income (expense), net 424 (7,609) 7,395 16,460
Income (loss) before provision for income tax (6,598) (12,324) (7,662) 6,300
Provision for income taxes 0 0 0 0
Net income (loss) before noncontrolling interests (6,598) (12,324) (7,662) 6,300
Net loss attributable to the noncontrolling interests 1,214 403 2,218 747
Net income (loss) attributable to PAVmed (5,384) (11,921) (5,444) 7,047
Less: Deemed dividend on Series C Convertible Preferred Stock     (26,460)  
Net income (loss) attributable to PAVmed common stockholders $ (5,479) $ (13,308) $ (12,467) $ 4,386
Per share information:        
Net income (loss) per share attributable to PAVmed common stockholders – basic (in dollars per share) $ (0.87) $ (22.08) $ (3.17) $ 8.23
Net income (loss) per share attributable to PAVmed common stockholders – diluted (in dollars per share) $ (0.87) $ (22.08) $ (3.17) $ 3.94
Weighted average common shares outstanding, basic (in shares) 6,269,384 602,822 3,938,037 533,068
Weighted average common shares outstanding, diluted (in shares) 6,269,384 602,822 3,938,037 1,809,099
Series B Preferred Stock [Member]        
Other income (expense):        
Less: Series B Convertible Preferred Stock dividends earned $ (95) $ (88) $ (189) $ (175)
Series C Preferred Stock [Member]        
Other income (expense):        
Less: Series B Convertible Preferred Stock dividends earned 0 (481) (145) (879)
Less: Deemed dividend on Series C Convertible Preferred Stock 0 (818) (6,689) (1,607)
Rights Liability [Member]        
Other income (expense):        
Change in fair value - rights liability $ 24 $ 0 $ 54 $ 0